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A B S T R A C T
Tacrolimus is a macrolide lactone and potent immunosuppressant. It is highly lipophilic and has very limited
aqueous solubility. Tacrolimus is highly susceptible to hydrolysis which results in very limited stability in aque-
ous solutions. Besides this, tacrolimus also undergoes dehydration and epimerization. Cyclodextrin (CD) complex-
ation can increase the solubility and stability of hydrophobic drugs in aqueous solutions through the formation
of drug/CD complexes. The aim of this study was to investigate degradation kinetics, mechanism and stability of
tacrolimus in aqueous CD solutions, with the ultimate goal of developing an aqueous vehicle for ophthalmic de-
livery. For this, phase-solubility and kinetic studies in aqueous solutions containing different CDs at different pH
values were performed. Mass spectrometry studies were also performed to elucidate the degradation mechanism
of the drug in aqueous CD solution. The study showed that the drug has maximum stability between pH 4 and
6 and hydrolysis was the main cause of tacrolimus degradation in aqueous 2-hydroxypropyl-βCD (HPβCD) solu-
tions. βCD and its derivatives were the better CD solubilizers for tacrolimus. The solubility and stability studies
were further conducted with CD and surfactants, which is tyloxapol, tween 80 and poloxamer 407, where the
combination provided better results compared to individual components.
1. Introduction
Tacrolimus (FK506) is a 23-membered macrolide lactone produced
by the bacterium Streptomyces tsukubaensis. It is a potent immunosup-
pressant used to prevent graft rejection after organ transplants (Akashi,
1996). Recent studies have found that immunomodulators like
tacrolimus are especially effective for the treatment of anterior inflam-
matory ocular disorders and can replace corticosteroids that frequently
cause cataract and induce glaucoma (Siegl, 2019). Similarly, in dis-
eases like atopic dermatitis and dry eyes, topical tacrolimus formula-
tions have been noted to have significant therapeutic efficacy (Arima,
2001). However, tacrolimus is a highly lipophilic compound and has
water solubility of only about 1 µg/ml. In addition to this, the drug is
susceptible to hydrolysis resulting in very low stability in aqueous solu-
tions (Siegl, 2019).
Cyclodextrins (CDs) are cyclic oligosaccharides of α-D-glucopyra-
nose with hydrophobic central cavity and a hydrophilic outer surface.
They are able to form inclusion complexes with several drugs pro-
vided that their structure (or part of it) fits in the CD cavity (Lofts-
son, 1989). No covalent bonds are formed or being broken during the
complexation and drug molecules in the complex are in rapid equilibria
with free molecules in the complexation media (Loftsson, 2005). The
complexation affects many physicochemical properties of drugs such
as their chemical stability and aqueous solubility (Loftsson, 1989). The
usage of natural CDs as drug carriers is restricted by their limited aque-
ous solubility but several hydrophilic CD derivatives have been synthe-
sized such as methylated, hydroxypropylated and sulfobutyl ether CD
derivatives (Arima, 2001). These hydrophilic CD derivatives can form
highly water-soluble complexes with lipophilic drugs.
No ophthalmic dosage formulation is commercially available for
tacrolimus. Though, many researchers have recently studied the effi-
cacy of topical tacrolimus for various allergic ocular diseases. Vichayon
et al. stated marked clinical responses with 0.1% tacrolimus ointment.
Hideshi et al. reported that 0.1% tacrolimus ophthalmic suspension
was viable to treatment of severe allergic conjunctivitis (Zhai, 2011;
Shoughy, 2017; Ohashi, 2010). These are the few of the reported
dosage for tacrolimus for ophthalmic use which showed efficacy. For
commercial eye drops, shelf-life of at least 3 years is desired (Bara-
nowski, 2014). However, there is a lack of proper and extensive sta-
bility data on the available studies. Surprisingly, it was mentioned that
0.1% tacrolimus ophthalmic solution was stable only for 20 days when
stored at 25 °C and for at 85 days or more when stored at 2–8 °C (Ez-
quer-Garin et al., 2017). Besides solubility and stability, various fac-
tors affect the physicochemical properties of eye drops like pH, drug
concentration, osmolality and viscosity (Sharma, 2016). There are few
reports on the use of CDs to improve the pharmaceutical characteris
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tics of tacrolimus, especially its solubility (Benelli, 1996; Mills,
1995). Mills et al. (Mills, 1995) assessed the efficacy of topical CD-en-
capsulated tacrolimus to prevent experimental corneal allograft rejec-
tion (Ezquer-Garin et al., 2017). Arima et al. (2000) have reported
improvement of tacrolimus solubility through complexation with var-
ious βCD derivatives ultimately leading to improved oral bioavailabil-
ity supported by faster dissolution rate of tacrolimus (Arima, 2001).
Nonetheless, the development of aqueous eye drop formulation contain-
ing tacrolimus is still a challenge, particularly due to its low chemical
stability and solubility.
Evaluation of drug degradation is important during the develop-
ment of pharmaceutical formulations to determine chemical degrada-
tion pathways and products as well as to estimate the product shelf-life.
Knowing the degradation pathways can facilitate stabilization of the
drug as degradation products can cause toxic side effects and other un-
wanted effects. Knowledge of drug stability and its degradation products
are essential during development of any pharmaceutical formulation
(Campos, 2017). Taking this into consideration, the objective of this
study was to investigate the chemical stability and kinetics of tacrolimus
in various CD solutions, elucidate the degradation mechanism and pro-
vide mode of stabilization. The ultimate goal was designing and devel-
oping a tacrolimus ophthalmic formulation containing CDs.
1.1. Theory
Tacrolimus is a complex 23-membered macrolide lactone with
L-pipecolic acid moiety adjacent to a masked tricarbonyl functional-
ity. It has 14 stereocenters, 3 double-bonds and a number of free hy-
droxyl groups and other functionalities (Skytte, 2013). There exists a
solvent-dependent equilibrium between cis and trans rotamers in solu-
tion due to restricted rotation of the amide bond in the pipecolic acid
moiety. Besides these, a different kind of equilibrium exists in polar sol-
vents with respect to cyclic ketal moiety. This equilibrium is explained
by tautomerism of tacrolimus where tacrolimus epimerizes to an inter-
mediate tautomer I(ring-opened tacrolimus) which is then converted to
tautomer II to reach an equilibrium containing the three forms (Skytte,
2013; Namiki, 1993; Peterka, 2019).
Tacrolimus can undergo several degradation and transformation
pathways such as dehydration, epimerization, rearrangement and iso-
merization of double bonds due to its structural characteristics (Myers,
2016). It is also highly susceptible to lactone hydrolysis under acidic
and basic conditions leading to formation of several products (Higuchi,
1965).
2. Materials and methods
2.1. Materials
Tacrolimus was purchased from Shanghai Huirui Chemical Technol-
ogy Co., Ltd. (China) and tacrolimus monohydrate (European Pharma-
copoeia (EP) Reference Standard) from Sigma-Aldrich. α-Cyclodextrin
(αCD), β-cyclodextrin (βCD), γ-cyclodextrin (γCD) and 2-hydroxy-β-cy-
clodextrin (HPβCD) with degree of substitution(DS) 4.2(MW 1380) were
kindly provided by Janssen Pharmaceutica, Belgium, 2-Hydrox-
ypropyl-γ-cyclodextrin (HPγCD) with DS 4.0–5.6
(MW 1540) by Chemical Marketing Concepts Europe, Netherland
and sulfobutyl ether β-cyclodextrin (SBEβCD) (sodium salt) with DS 4.8
(MW 2163) by CyDex Pharmaceuticals, Lenexa. 2-Hydroxypropyl-α-cy-
clodextrin (HPαCD) with DS 0.6(MW 1180), and randomly methylated
β-cyclodextrin (RMβCD) with DS 12.6(MW 1312) were purchased from
Wacker Chemie (Munich, Germany). Similarly, we purchased Ethyl-
enediaminetetraacetic acid (EDTA), tyloxapol reagent grade and polox-
amer 407 from Sigma-Aldrich, USA and tween 80 from Tokyo Chem-
ical Industry Co., Ltd. Japan. Milli-Q water was used for the prepara-
tion of all solutions and the mobile phase for UHPLC measurements. All




Quantitative determination of tacrolimus was performed on a re-
versed-phase ultrahigh-performance liquid chromatographic (UHPLC)
component system from Thermo Fisher Scientific Vanquish HPLC system
consisting of VF-P10-A pump, a VF-A10-A autosampler, VH-C10-A col-
umn compartment, VWD-3100 UV–Vis detector operated at 205 nm and
a Phenomenex Kinetex C18 1.7 µm 100 × 2.1 mm with a security guard
ULTRA HOLDER. The column temperature was 50 °C and the mobile
phase consisted of acetonitrile(ACN) and Milli Q water containing 0.1%
(v/v) trifluoroacetic acid (60:40). The flow rate was 0.4 ml/min, sample
injection volume was 10 µl and the retention time(RT) was 3 min.
2.2.2. Buffers
Hydrochloric acid–potassium chloride buffer (pH 2), citrate buffer
(pH 3–6), phosphate buffer (7–8) and carbonate-bicarbonate buffer (pH
9) was prepared by mixing aqueous solutions of the acid with the aque-
ous solutions of the corresponding salt. The concentration of the buffer
salts was 0.1 M. The ionic strength of the media was not adjusted. Also,
volatile buffers like 20 mM ammonium bicarbonate, ammonium hydrox-
ide and formic acid were used in the mass spectroscopic studies.
Various amounts (expressed as % w/v) of different CDs were added
to the buffer solutions when the effects of CDs were investigated.
2.2.3. Kinetic studies
The tacrolimus degradation was investigated by adding stock solu-
tion (100 µl) of the drug in methanol to aqueous buffer solution (5 ml),
previously equilibrated at 40 °C in a heating block, and mixed thor-
oughly. The initial tacrolimus concentration was 2.48 mM. The pH of
the final reaction mixture was determined at the end of each experi-
ment with a pH meter standardized at 40 °C. All reactions were run un-
der pseudo-first-order conditions. Aliquots (10 µl) were injected into the
column at various time intervals, and the pseudo-first-order rate con-
stant (kobs) determined by linear regression of natural logarithm of the
remaining drug concentration vs time plots.
2.2.4. MS quad/LC-MS studies for degradation products
All samples for mass spectrometer (MS) studies were prepared as
described above in the kinetics studies (Section 2.2.3) except for the
buffers where only MS-compatible buffers were used. The samples were
diluted with the mobile phase before analyzing by Waters ACUITY
UPLCTM (Waters Corporation, Milford, MA, USA) coupled to Waters
QToF SYNAPT G1 mass spectrometer (Waters MS Technologies, Man-
chester, UK). The UPLC system was equipped with a binary solvent de-
livery system and autosampler. Chromatographic analysis of tacrolimus
degradation products was conducted on an ACQUITY UPLC BEH C18
column (2.1 mm × 100 mm, 1.7 µm; Waters corp., Milford, MA, USA).
The mobile phase consisted of solvent A: 10 mM ammonium acetate in
water pH 5.5, and solvent B: 10 mM ammonium acetate in ACN pH 5.5.
Gradient elution was used at a flow rate of 0.50 ml/min as follows: ini-
tial 40%B 0–0.1, linear gradient from 0.1 to 5 from 40%B to 100%B,
holding at 100%B 5–5.5, linear gradient from 100%B to 40%B 5.5–5.6
and holding at 40%B 5.6–7 min.
The injection volume was 4 µl. The Synapt G1 QToF-MS mass spec-
trometer was operated in positive electrospray ionization mode (cap-
illary voltage 3.2 kV, source temperature 120 °C, desolvation tempera-
ture 400 °C, cone gas flow 50 L/h, desolvation nitrogen gas flow 800
L/h). Ions with mass range 50–1000 m/z (mass to charge ratio) were
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MS system and data acquisition were controlled by the MassLynx v4.1
software (Waters Corp., Milford. USA).
2.2.5. Solubility studies
Solubility studies were determined by adding an excess amount of
tacrolimus to aqueous solutions containing various concentrations of CD
at around pH 5. The suspensions formed were sonicated in an ultrasonic
bath (Edmund Buhler GmbH) for 90 min. The vials containing these sus-
pensions were then shaken at room temperature. After equilibrium for
24 hrs, and aliquots were filtered through a 0.45 µm membrane filter
unit (Phenomenex, UK), diluted with 50% aqueous acetonitrile solution
(whenever necessary) and analyzed by UHPLC.
Higuchi and Connors (1965) have described the different phase-sol-
ubility profiles: A-type phase-solubility profiles can be related to the wa-
ter-soluble CD derivatives and the B types to the less soluble natural
CDs (Saokham, 2018). The drug solubility increases with increasing
CD concentration in the A-type profiles due to formation of water-solu-
ble drug/CD complexes. While B-type profiles are related to formation
of complexes that have limited solubility in water. For B-type profiles
an initial increase in drug solubility is observed with increasing CD con-
centration, then a plateau is formed, where the dissolved drug concen-
tration is at its maximum, followed by a decrease in the total concen-
tration of dissolved drugs (Jansook et al., 2018). The most common
complex observed is the 1:1 drug/CD complex where one drug molecule
(D) forms a complex with one CD molecule:
(1)
Such 1:1 complex display AL-type phase-solubility profiles and the
stability constant of the complex (K1:1) can be calculated from the equa-
tion (2) where S0 is the apparent intrinsic solubility of the drug in
the complexation media when no CD is present. The value of K1:1 is
frequently between 50 and 2000 M−1 with a reported mean value of
490 M−1 for βCD (Loftsson et al., 2005; Brewster and Loftsson,
2007).Fig. 1
(2)
When a drug molecule forms a complex with more than one CD
molecule, a consecutive complexation is assumed, thus stability con
Fig. 1. Chemical Structure of Tacrolimus.
stants of higher-order complexes (K1: n) should be calculated using a dif-
ferent model (Loftsson et al., 2005). The most common stoichiometry
is the formation of 1:2 D/CD complexes, where one drug molecule forms
a complex with two CD molecules:
(3)
AP phase-solubility types are usually observed under such conditions.
Equation (4), which is a quadratic model allows the estimation of both
stability constants (K1:1 and K1:2). The value of K1:2 is often in the range
10 to 500 M−1 or significantly lower than that of K1:1 (Loftsson et al.,
2005; Loftsson et al., 2005)
(4)
Determination of the complexation efficiency (CE) can be a better al-
ternative to K1:1 to compare the solubilizing effect of CDs (Loftsson et
al., 2007). The CE determination (Equation (5)) has less variation be-
cause it can be calculated from only the slope of the linear phase-solu-
bility diagram (Loftsson et al., 2005; Loftsson, 2014; UEKAMA and
HIRAYAMA, 1987).
(5)
3. Results and discussions
3.1. Influence of cyclodextrin concentration
The degradation of tacrolimus has been shown to follow
pseudo-first-order kinetics in aqueous buffer CD solutions at constant pH
and temperature. This kinetic behavior was not affected even by intro-
duction of up to 7.5% (w/v) HPβCD to the reaction medium as a linear
relationship was obtained in all cases between the logarithms of the per-
cent of the remaining drug concentration and time (Fig. 2).
Increasing the HPβCD concentration in the reaction medium de-
creases the rate of degradation of tacrolimus and a non-linear relation-
ship is obtained between the pseudo-first-order rate constants calculated
from the slopes is plotted against the HPβCD concentration (Fig. 3).
The rate decreases fast when the HPβCD concentration is increased from
2.5% to 5% but then levels off at 7.5%. These results are consistent with
a kinetic system where a drug degrades at a higher rate outside the CD
inclusion complex than within the complex (Lineweaver and Burk,
1934; Il’ichev et al., 2007):
(6)
where K1:1 is the complex stability constant, kc is the observed
first-order rate constant for the drug degradation within the complex
(D/CD) and kf represents the observed first-order rate constant for the
degradation of the free drug (D). Here D represents the drug tacrolimus.
The observed first-order rate constant (kobs) for the drug degradation is
the weighted average of kf and kc:
(7)
where ff is the fraction of drug in solution that is unbound (i.e. free)
and fc is the fraction of drug in solution that is bound in a CD complex.
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Fig. 2. Representative first-order plots (ln (drug concentration remaining) against time) for the degradation of tacrolimus in aqueous a) 5%HPβCD at pH 9, (b) 2.5%HPβCD at pH 5, (c)
2.5%HPβCD pH at 7.4,8 and 9 and (d) 5%HPβCD at pH 6 and 7.4 at 40 °C.
Fig. 3. The effect of HPβCD concentration on the observed rate constant for tacrolimus
degradation in aqueous buffer solution at pH 7.4 at 40 °C. The initial tacrolimus concen-
tration [D]T was kept constant at 2.48 mM but the HPβCD concentration [CD]T ranged
from 0 to 7.5% (w/v).
where [CD] is the concentration of the free (i.e. unbound) CD in
the aqueous medium. If the total CD concentration (i.e.
[CD]T = [CD] + [D/CD]) is much greater than the total drug concen-
tration (i.e. [D]T = [D] + [D/CD]) then [CD] ≈ [CD]T:
(9)
Rearrangement of Equation (9) gives Equation (10) (Ruth and
Chika, 2018):
(10)
Knowing kf, both kc and K1:1 can be calculated after construction
of Lineweaver-Burk plot (Fig. 4) using Equation (10). The value of kc
is obtained from the ordinate intercept and kf, and K1:1 is obtained by
dividing the slope into the ordinate intercept. The values of kc were
smaller but were affected by the media pH like those of kf. The K1:1
was less affected by pH, being almost identical at all pH values tested.
Tacrolimus does not contain ionizable moiety and is, thus, unionized at
all pH values tested. However, the buffer salts and ionic strength can af-
fect the value of K1:1.
Fig. 4
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3.2. Degradation profile of tacrolimus in aqueous cyclodextrin solution and
proposed degradation mechanism
First, the degradation rate of tacrolimus was calculated in aque-
ous 5% HPβCD solutions with and without 0.1% EDTA. EDTA forms
complexes with metal ions that can catalyze oxidative degradation of
tacrolimus. No significant difference in rate constant was observed as
shown in Table 1. Similar results were observed when the degradation
studies were done with and without purging the reaction media with ni-
trogen. This showed that oxidation is probably not a major degradation
pathway in aqueous CD solutions.
Profiling and identification of degradation products was carried out
using UHPLC-MS. Degradation products were identified in our study
by determining the mass/charge (m/z) values, fragmentation pathway
and chromatographic properties. Under acidic conditions, tacrolimus
(RT 4.04 min) degradation was relatively slow. Tacrolimus degradation
in CD buffer solution at pH 2.5 yielded a mixture of two compounds
that were more polar than tacrolimus with retention times (RT) of 2.88
and 2.90. Both had identical masses 844 [M + Na] +. Mass spectra
and fragmentation data of the two compounds were similar, practically
indistinguishable from each other and thus the two compounds could
be isomers. The MS data of these compounds when analyzed by Mass
Lynx software coincided with the hydrolyzed form of tacrolimus at its
lactone group. Similar results have been observed during degradation
Table 1
Values of observed rate constants(kobs) of tacrolimus in HPβCD solution at pH 5 and 9 with
and without 0.1% EDTA.
kobs (h −1) pH 5 pH 9
With 0.1% EDTA 0.0014 0.96
Without EDTA 0.0016 0.91
of tacrolimus related compounds, like everolimus and sirolimus, where
the lactone group is hydrolyzed as explained by Il’ichev et al. (Il’ichev
et al., 2007) (Nogueiras-Nieto, 2012). Another less polar compound
was obtained at 4.38 RT with m/z 808. The MS data indicated that de-
hydration might have occurred with a loss of water molecule resulting
in formation of a less polar compound.
Tacrolimus degradation appeared to be completed within 1 h at pH
10. The basic condition also yielded a mixture of two compounds that
are more polar than tacrolimus with retention time of 2.90 and 2.99.
Both had identical masses 844 [M + Na] +. The compounds were sim-
ilar to the one obtained under acidic conditions. This suggests that
the hydrolyzed form of tacrolimus obtained at acidic and basic condi-
tions could all be isomers since all gave the same elemental composi-
tion and similar fragmentation data. Another major degradation prod-
uct formed under basic condition had a longer retention time (RT 3.38)
than the other degradation compounds but was slightly more polar
than tacrolimus (RT 4.04) with m/z 826 [M + Na] +. It was identi-
fied as the open-chain form of compound formed by dehydration of
tacrolimus molecule under acidic conditions by the elemental compo-
sition from the MS data. Skytte et al (2012) observed the formation
of same compound when they treated tacrolimus with 1,5-diazabicyclo
[4.3.0] nonene (DBN) in dichloromethane (basic conditions) (Skytte,
2013). Based on the structure of this compound, it looks like tacrolimus
has undergone hydrolysis at lactone group and a dehydration reaction to
form a double bond. The proposed degradation mechanism of tacrolimus
in HPβCD solution can be represented in Fig. 5.
3.3. Effect of pH (pH rate profile)
The influence of pH on the degradation of tacrolimus in aqueous
HPβCD buffer solutions was investigated over the pH range of 2–9. The
ionic strength of the buffer was not controlled. The pH-rate profiles
for the observed first-order degradation of tacrolimus in aqueous solu
Fig. 5
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tions containing 2.5, 5.0 and 7.5% (w/v) of HPβCD at 40 °C are shown
in Fig. 6.
The kinetics of the drug degradation in CD solution is sensitive to the
medium acidity as shown by the pH-rate profile in Fig. 6. The pH-rate
profile consisted of plateau region in the pH range of 4–6, small increase
in degradation rate between pH 2 and 3, and a sharp increase at pH 6.
The drug (pka 10) is in its unionized form at all pH values tested. Table
2 shows the kc and kf for tacrolimus in HPβCD solutions at different pH
values and 40 °C.
This clearly shows that the tacrolimus degradation decreases with in-
creasing CD concentration, with degradation being relatively fast when
there is no CD present. The drug is most stable at pH between 4 and
6, both in aqueous CD solutions and in CD free medium. We can also
see that kf > kc at all pH values showing that drug degrades at a higher
rate outside the CD complex than within the complex at all pH tested. kc
and kc follow similar profile as shown in Fig. 7. Consequently, the drug
degradation within the CD complex and outside the complex follow sim-
ilar reaction pathways.
The shapes of both curves (i.e. for kf and kc) show that the hydrol-
ysis reaction of tacrolimus in aqueous CD solutions and CD free media
consist of three regions, that is the specific acid-catalyzed (i.e. H3O+ cat-
alyzed) region at pH below about 3, an uncatalyzed region or plateau
between pH 3 and 7, and a specific base-catalyzed (i.e. OH– catalyzed)
region at pH above about 7.4. For pH values below 3, both the curve has
negative slope and the kc and kf in Equations (11) and (12) are domi-
nated by kH and kH́, respectively, and this hydrolysis reaction proceeds
according to the reaction pathway catalyzed by H3O+ ions. The zero
slope of the curves, presented for pH values 4–6 indicates that in this pH
range, the ko and kó are dominating, and from pH 7.4 onwards, kOH and
kÓH are dominating since the hydrolysis is catalyzed by HO– ions. The
rate of hydrolysis is dependent upon the pH of the medium and both kc




pH rate (kobs h−1) profile for tacrolimus in HPβCD solution at 40˚C.
where kH and kH́ are acid-catalyzed, ko and kó uncatalyzed and kOH
and kÓH being basic-catalyzed rate constants.
The values of kH, kH́, ko, kó, kOH and kÓH for different reaction
pathways that constitute the whole hydrolysis process were determined.
Table 3 shows the values for these constants and the definitive expres-
sion of the kf and kc at 40 °C is given by Equations (13) and (14).
(13)
(14)
These results show that the hydrolysis reactions of tacrolimus (both
in CD and CD free solutions) follow acid-base catalysis mechanism
where the reaction pathway catalyzed HO– ions is dominant and the
degradation of tacrolimus is fastest in basic medium.
3.4. Influence of different Cyclodextrins
The stability studies above in aqueous HPβCD media show that the
drug is most stable at pH about 5 but the degradation rate is acceler-
ated under basic conditions or at pH above 7.4. The effect of αCD and
βCD on the tacrolimus degradation was also tested (Table 4). However,
tacrolimus does not readily form a complex with γCD and, thus, this CD
was omitted from this part of the study.
αCD and βCD give lower kc values than HPβCD at both pH values
tested. The kf /kc ratios show that under all conditions tacrolimus is sta-
bilized by the CD complexation. βCD results in the lowest kc values and
the highest K1:1 values in comparison to αCD and HPβCD and, thus, is
the best stabilizer of the three CDs tested.
3.5. Phase-solubility studies
Different CDs were used to determine the solubility of tacrolimus
in aqueous solutions by the phase-solubility method of Higuchi and
Connors (1965) (Saokham, 2018). A preliminary study indicated that
tacrolimus degraded during autoclaving and was not chemically stable
in aqueous solution during a 7-day equilibration at room temperature.
Thus, the solubility studies were carried out by sonicating the aqueous
CD media containing excess of tacrolimus for 90 min and equilibration
in a rotary shaker at room temperature for 24 hrs. Fig. 8 shows the
phase-solubility diagrams of tacrolimus in various CD solutions in pure
(i.e. unbuffered) water at around pH 5 at room temperature.
The solubility of tacrolimus in pure water is extremely low (1.58 µM
in water at 25 °C) (Arima, 2001). Two different types of phase-solu-
bility diagrams were observed, AL-type where strictly linear relationship
is observed and AP where positive deviation from linearity is observed.
AL and AP were distinguished by comparing the correlation coefficient
squared values (r2). The solubility curves with r2 values greater than
0.99 were regarded as AL-type and those displaying r2 values of less than
0.99 were regarded at AP-type (Loftsson, 2014)[26].
αCD, HPαCD and SBEβCD gave r2 values of greater or equal to 0.99,
regarded as AL-type and the stability constants (K1:1) calculated using
Equation (2). Whereas, all the other CDs gave r2 values less than 0.99,
the phase-solubility diagrams considered to be of AP-type and the sta-
bility constants, K1:1 and K1:2, calculated using Equation (2) and (4),
respectively.
Table 2
Values of kf, kc and K1:1 for tacrolimus in HPβCD solutions in the pH range of 2–9.
pH: 2 3 4 5 6 7.4 8 9
kf (h −1) 0.032 0.019 0.0175 0.0175 0.0175 0.07 0.28 5
kc (h −1) 0.013 0.0071 0.0070 0.0069 0.0071 0.0072 0.037 1.18
kf/kc 2.5 2.7 2.5 2.5 2.5 9.7 7.6 4.2
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Fig. 7
Log kf (●) and log kc (○) of tacrolimus in HPβCD solution at 40˚C. The rate constants (i.e.
kf and kc) are first-order and have the unit h−1.
Table 3
Values of kH, kH́, ko, kó, kOH and kÓH in aqueous HPβCD solution.
kH kOH ko
3.2 M −1h −1 1.73 × 10 5 M −1h −1 0.016 h −1
kH́ kÓH kó
1.3 M −1h −1 4.09 × 10 4 M −1h −1 6.76 × 10 -3h −1
Table 4
Values of kc, kf and K1:1 of tacrolimus at 40˚C and pH 5 or 9 in aqueous CD solutions.
pH 5 9
CD αCD βCD HPβCD αCD βCD HPβCD
kf (h −1) 0.0175 0.0175 0.0175 5 5 5
kc (h −1) 0.0035 0.003 0.00716 1.02 0.97 1.18
kf/kc 5 5.8 2.5 4.9 5.1 4.2
K1:1 (M −1) 65.63 1170 44.9 419 2515 47.35
The analysis of the 1:3 and 1:4 (guest: host) inclusion models gave
negative values for the stability constants suggesting that tacrolimus pre-
dominantly forms 1:1 and 1:2 complexes with these CDs under men-
tioned conditions. The stability constant for all the CDs tested are listed
in Table 5. It should be noted that the values of the stability constants
given in Table 5 are obtained from phase-solubility profiles at room
temperature where aqueous CD solutions are saturated with the drug
while the values in Table 4 are obtained at 40 °C in dilute solutions.
In general, the values of the stability constants decrease with increasing
temperature.
Among the natural CDs, βCD had the highest stability constant sug-
gesting that the βCD cavity was of appropriate size. The hydroxypropyl
derivatives of the natural αCD and βCD had inferior stability constant
compared to natural CDs. While of the CD derivates RMβCD had
the highest stability constant (K1:1). This high value for the RMβCD com-
plex was consistent with other results of other drugs and is due to the
increase in hydrophobic space of the βCD cavity upon methylation of the
OH-groups. The K1:1 value for RMβCD was marked higher than the K1:2
value, showing that the 1:1 complex to be favored at the RMβCD con-
centrations tested.
Interestingly, SBEβCD gives AL-phase-solubility diagram while
HPβCD gives an AP diagram. This may be because of the negative
charges on the SBEβCD molecule which might reduce the possibility
of formation of tacrolimus/SBEβCD 1:2 complexes due to charge repul-
sion. The reduced ability of HPβCD and HPαCD to form complex with
tacrolimus compared to the natural CDs might be due to steric hindrance
of the substituent groups at the CD cavity.
3.6. Effect of different surfactants on tacrolimus stability and solubility in
HPβCD solution
Even though the CDs were able to stabilize tacrolimus in solution,
the stability obtained was not sufficient to move the drug toward the for-
mulation step. So, different surfactants were also tested in combination
with the CDs to improve further the chemical stability of tacrolimus in
aqueous media. Poloxamer 407, tyloxapol and tween 80 were used for
this purpose. Aqueous solutions containing 5% (w/v) HPβCD and surfac-
tant (from 0 to 5% w/v) were prepared to which 100 µl of tacrolimus
stock solution (2.48 mM) was added. These solutions were subjected to
one cycle of autoclaving and the remaining drug concentration was mea-
sured by using the UHPLC method (Fig. 9).
Fig. 9b shows that drug degradation decreases with increasing
poloxamer concentration up to 3% where the degradation again in-
creases from 5%. This was observed either when only poloxamer or com-
bination of poloxamer and CD were used. Similar trend is observed in
Fig. 9c showing the drug degradation in aqueous CD solutions con-
taining tyloxapol. In case of tyloxapol, drug degradation is minimum
at 2% and then increases upon increasing tyloxapol concentration (for
both, the combination of HPβCD and tyloxapol and only tyloxapol).
Likewise, maximum tacrolimus stability was observed in 5% HPβCD so-
lution containing 1% tween 80(Fig. 9a). Pure aqueous solutions con-
taining more than 2% tween 80 individually provided more stability
than when combined with HPβCD while the combination of poloxamer
407 and tyloxapol with HPβCD provided more stability in all cases than
the pure polymers and CD. More than 90% of drug is degraded upon
heating in an autoclave (121 °C for 20 min) when only 5%HPβCD is pre-
sent in the degradation media but the tacrolimus degradation dropped
to about 30% and 40% when 2% tyloxapol and 3% poloxamer were pre-
sent in the HPβCD media, respectively. The stabilizing effect of the sur-
factants might be due to micelle formation and protection of tacrolimus
within the micelles (Santos Akkari, 2016).
Tyloxapol and poloxamer 407 were then used to evaluate the solu-
bility of the drug along with 5% HPβCD as the combination of HPβCD
with them increased the stability of the drug. Fig. 10 shows the solu
Fig. 8
Phase-solubility diagrams of tacrolimus in CD in pure water at room temperature. Each point represents the mean of triplicate experiments. Key: (●) αCD; (○) βCD; (△) γCD; (▲) HPβCD;
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Table 5
Stability Constants (K1:1 and K1:2)
a of tacrolimus/CD complexes in pure water at room
temperature.









a K1:1: Stability constant of 1:1 complex, K1:2: Stability constant of 1:2 complex
bility of tacrolimus in 5% HPβCD along with various % of poloxamer
and tyloxapol.
We showed that poloxamer was able to slightly increase (about 1.2
folds) the solubility of tacrolimus. The solubility did not increase with
increasing concentrations of poloxamer
(Fig. 10a). Addition of poloxamer to the complexation media results
in competition with drug molecules for the CD cavity and consequent
displacement of the drug molecules from the CD cavity (Muankaew,
2014). The slight increase in solubility may indicate that a decrease
in solubility due to the competitive displacement is proba
bly compensated by the solubilizing effect of polymer micellization (Fig.
10a). On the contrary, Akkari et al.(2015) observed that the increase
in aqueous solubility of hydrophobic drugs, in the presence of poly-
mer and CD (compared to isolated systems), suggesting no or little in-
fluence of drug-polymer competition for the HPβCD cavity [34]. Those
observations go in the line with our results where tacrolimus solubil-
ity in aqueous 5% HPβCD solution is improved by the addition of ty-
loxapol (Fig. 10b). The tacrolimus solubility increased with increasing
tyloxapol concentration. The combination of tyloxapol and HPβCD sol-
ubilize more than the individual component giving the maximum sol-
ubility of 0.3 mM at 5% tyloxapol. Tyloxapol, a non-ionic surfactant
oligomer, might improve the solubility of drug by either improving drug
wettability or micellar incorporation of drug and drug/CD complexes in
case of HPβCD [35].
4. Conclusions
The stability of tacrolimus in CD solution was determined as a func-
tion of the medium acidity and tacrolimus shown to be more stable
at acidic pH than at basic pH. Moreover, CD has a stabilizing effect
at all pH values tested as observed by comparing the rate constants of
the free and bound drug (i.e. within the complex). Tacrolimus degra-
dation in CD solutions is mainly due to hydrolysis of the lactone link-
age (occurred under both acidic and basic conditions), dehydration,
or simultaneous hydrolysis and dehydration to yield the final prod-
uct as confirmed by the MS studies. βCD and its derivates increased
Fig. 9
Drug degradation % after one cycle of autoclaving with 5%(w/v) HPβCD and various % (w/v) of surfactants (a) with tween 80, (b) with poloxamer 407 and (c) with tyloxapol.
Fig. 10
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tacrolimus solubility much more than the other CDs tested. The stability
and solubility were improved when combination of CD and surfactants
was used, particularly with HPβCD and poloxamer 407 or tyloxapol.
However, tacrolimus was not adequately chemically stable to be formu-
lated as aqueous eye drops.
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